Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The antiviral drug could put a dent into the uptake of COVID-19 vaccines, as countries still struggle to reach herd immunity due to vaccine hesitancy.

Moderna and BioNTech plummet more than 15% following news of Merck's COVID-19 antiviral pill

Takeda Pharmaceutical

Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine. The contamination led to the withdrawal of 1.63 million doses of the mRNA shot from Japan in August.

Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines

An investigation carried out by Moderna and the Spanish manufacturer Rovi found that the issue was caused by incorrect assembly of the vaccine vials

‘Human Error' Caused Contamination Of Moderna Vaccines In Japan, Distributor Takeda Says

The company won't have to turn away customers.

This Detail May Be Worth Billions for Moderna

The Food and Drug Administration is leaning toward approving a half-dose of Moderna's COVID-19 vaccine as a booster shot, according to a report.

FDA considering half-dose of Moderna vaccine as booster

Novavax

It's not because any of the vaccine makers reported bad news.

Why Moderna, BioNTech, and Novavax Stocks Are Tanking This Week

The company is building a new research and development center.

Why Moderna Is up Today While the Market Is Down

SPDR S&P 500 ETF Trust

If September's bow to market seasonality is any indication, it's time for bulls to be very fearful of this trio of large-cap stocks. The post 3 Large-Cap Stocks to Sell or Short appeared first on InvestorPlace.

3 Large-Cap Stocks to Sell or Short

Moderna, Inc. (NASDAQ: MRNA), which made a windfall with its COVID-19 vaccine program, is plowing back some of the largesse into R&D. What Happened: Moderna announced Thursday it's investing in a new science center, known as the Moderna Science Center, at 325 Binney Street in Cambridge, Massachusetts.

Why Moderna Is Investing In A New Science Center

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to invest in new science center in Cambridge, MA.

Moderna to Invest in New Science Center in Cambridge, MA

Vertex Pharmaceuticals

Here are the top biotech picks from three Motley Fool contributors.

3 Winning Biotech Stocks to Buy Hand Over Fist

Is (MRNA) Outperforming Other Medical Stocks This Year?

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

Close on heels of the U.S. Food and Drug Administration issuing restricted authorization for the Pfizer Inc. (NYSE: PFE)-BioNTech SE - ADR (NASDAQ: BNTX) COVID-19 booster vaccine dose, it is also expected to greenlight rival vaccine maker Moderna Inc.'s (NASDAQ: MRNA) half-dose mRNA vaccine as a booster shot, reported Bloomberg, citing people familiar with the matter Moderna's COVID-19 vaccine is approved for use in adults as well as adolescents in two-dose series of 100mcg each, given 28 days apart. The FDA has also authorized an additional dose for moderately-to-severely immunocompromised people at least 28 days after the initial two-dose primary series.

Is Moderna's Booster COVID-19 Shot Moving Closer to Authorization?

Pfizer

Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Today

Someone with a lot of money to spend (and possibly insider knowledge) has taken an unusually bearish stance on Moderna. And retail traders should know.

Tracking Moderna's Smart Money Trades

Will Moderna Stock Reach $500?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at Chardan's Virtual 5th Annual Genetic Medicines Conference.

Moderna to Present at Chardan's Virtual 5th Annual Genetic Medicines Conference

The biotech's COVID-19 vaccine sales could sink once the pandemic is over.

Moderna CEO Predicts Pandemic Could End in 2022: Here's Why the Stock Could Plunge If He's Right

IDEXX Laboratories

MercadoLibre

Atlassian

None of it has anything to do with business fundamentals.

Why Are the Nasdaq's Top Growth Stocks Freaking Out Monday?

Volatility remains high among vaccine stocks as two CEOs predict the end of the pandemic next year.

Why BioNTech, Moderna, and Novavax Stocks Are Sliding Today

Sorrento Therapeutics Inc

Are Redditors Being Fooled By Corporate Showmanship? “If you can't dazzle them with brilliance, baffle them with bullsh*t.

Skip the Bullsh*t! CEO Speak Reveals 2 Reddit Stock Gems

Today, Benzinga's options scanner spotted 18 uncommon options trades for Moderna (NASDAQ:MRNA). The overall sentiment shows 55.56% of the big-money traders are bullish on the stock and 44.44%, bearish.

This Is What Smart Money Is Betting On Moderna

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces supply agreement with Peru for 20 million doses of its COVID-19 vaccine.

Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine

NVIDIA

U.S. indices were trading higher and continuing to gain as investors weigh Wednesday's Fed decision to keep rates unchanged. Markets also rebounded following recent weakness driven by China volatility.

Moderna And Nvidia Lead The Nasdaq-100

On Thursday, Morderna Inc. (NASDAQ:MRNA) CEO told the Swiss newspaper Neue Zuercher Zeitung the coronavirus pandemic could be over in a year. Zeitung thinks increased vaccine production and the potential to vaccinate children could render the world free of the pandemic in a year's time.

News for Moderna Stock (MRNA)